NCT03522259 - Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery | Biotech Hunter

Enrollment

272

Participants

Timeline

Start Date

July 19, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Bariatric Surgery

Interventions

DRUG

Rivaroxaban 10 MG Oral Tablet [Xarelto]

Rivaroxaban 10mg per os is started on the first postoperative day. Patients receive Rivaroxaban 10mg QD for 7days (short arm) or 28 days (long arm)

Trial Locations (3)

University Hospital, Inselspital Berne, Bern

Kantonsspital Baden, Baden

Clinic Beau-Site, Bern